2026-04-13T07:12:47Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/123802025-10-24T10:18:19Zcom_2072_378070com_2072_378040col_2072_378092

7317 CAHtalyst Pediatric: Results From The Randomized, Double-Blind, Placebo-Controlled Period Of A Phase 3 Trial Of Crinecerfont, A Corticotropin-Releasing Factor Type 1 Receptor Antagonist, In Children And Adolescents With Classic Congenital Adrenal Hyperplasia Sarafoglou, Kyriakie Kim, Mimi Lodish, Maya Felner, Eric Martinerie, Laetitia Nokoff, Natalie Clemente, Maria Institut Català de la Salut [Sarafoglou K] University of Minnesota Medical School and College of Pharmacy, Minneapolis, MN. [Kim MS] Children’s Hospital of Los Angeles, Los Angeles, CA. Keck School of Medicine of USC, Los Angeles, CA. [Lodish M] University of California San Francisco, Berkeley, CA. [Felner EI] Emory University School of Medicine, Atlanta, GA. Children’s Healthcare of Atlanta (CHOA), Atlanta, GA. [Martinerie L] Hôpital Universitaire Robert Debré, AP-HP, Université Paris Cité, Paris, France. [Nokoff NJ] University of Colorado Anschutz Medical Campus, Aurora, CO. [Clemente M] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Instituto de Salud Carlos III, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Infants Malalties congènites - Tractament Hiperplàsia - Tractament ACTH NAMED GROUPS::Persons::Age Groups::Child DISEASES::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Congenital Abnormalities::Urogenital Abnormalities::Disorders of Sex Development::Adrenogenital Syndrome::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Adrenal Hyperplasia, Congenital CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, G-Protein-Coupled::Receptors, Corticotropin-Releasing Hormone DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::niño ENFERMEDADES::enfermedades y anomalías neonatales congénitas y hereditarias::anomalías congénitas::anomalías urogenitales::trastornos del desarrollo sexual::síndrome adrenogenital::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades y anomalías neonatales congénitas y hereditarias::hiperplasia suprarrenal congénita COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores acoplados a proteínas G::receptores de hormona liberadora de corticotropina Corticotropin-releasing factor; Children; Classic congenital adrenal hyperplasia Factor alliberador de corticotropina; Nens; Hiperplàsia suprarenal congènita clàssica Factor liberador de corticotropina; Niños; Hiperplasia suprarrenal congénita clásica 2025-01-08T11:05:23Z 2025-01-08T11:05:23Z 2024-10-05 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Sarafoglou K, Kim MS, Lodish M, Felner EI, Martinerie L, Nokoff NJ, et al. 317 CAHtalyst Pediatric: Results From The Randomized, Double-Blind, Placebo-Controlled Period Of A Phase 3 Trial Of Crinecerfont, A Corticotropin-Releasing Factor Type 1 Receptor Antagonist, In Children And Adolescents With Classic Congenital Adrenal Hype. J Endocr Soc. 2024 Oct 5;8(Supplement_1):bvae163.127. 2472-1972 https://hdl.handle.net/11351/12380 10.1210/jendso/bvae163.127 http://hdl.handle.net/11351/12380 eng Journal of the Endocrine Society;8(Supplement_1) https://doi.org/10.1210/jendso/bvae163.127 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf Oxford University Press Scientia